Showing 4431-4440 of 7102 results for "".
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humirahttps://practicaldermatology.com/news/sandoz-proposed-biosimilar-shows-equivalent-efficacy-to-humira/2458256/Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. The primary endpoint of the study was the proportio
- BTL Aesthetics To Unveil New Ultra Femme 360° Technology for Vaginal Rejuvenation at AADhttps://practicaldermatology.com/news/btl-aesthetics-to-unveil-new-ultra-femme-360-technology-for-vaginal-rejuvenation-at-aad/2458263/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- Suzanne Olbricht, MD, Named New Chief of Dermatology at Beth Israel Deaconess Medical Centerhttps://practicaldermatology.com/news/suzanne-olbricht-md-named-new-chief-of-dermatology-at-beth-israel-deaconess-medical-center/2458278/Suzanne Olbricht, MD, is the new Chief of Dermatology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She will also serve as President of the American Academy of Dermatology in 2018. From 1983 to 1997, Dr. Olbricht worked as a staff derma
- No Biopsy Required? Non-Invasive Skin Cancer Test May Offer Quick Diagnosishttps://practicaldermatology.com/news/no-biopsy-required-non-invasive-skin-cancer-test-may-offer-quick-diagnosis/2458284/A new non-invasive imaging technique may accurately detect skin cancer without surgical biopsy. Multiphoton microscopy of mitochondria accurately identified melanomas and basal cell carcinomas by detecting abnormal clusters of mitochondria in both types of skin cancer, according to resear
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- Allergan to Acquire ZELTIQ for $2.47 Billionhttps://practicaldermatology.com/news/allergan-to-acquire-zeltiq-for-247-billion/2458291/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary